Email
Print
Prescription Hormonal Drugs In Gynecology Market - Forecast(2024 - 2030)
Prescription Hormonal Drugs In Gynecology Market Overview
Prescription Hormonal Drugs In Gynecology Market Size is estimated to reach $56.7 billion by 2027 and is poised to grow at a CAGR of 5.8% over the forecast period of 2022-2027. Several gynecological illnesses involve hormonal shifts. The growth and differentiation of uterine tissue as well as proper ovulatory function depend on the hypothalamus-pituitary-ovarian (HPO) axis operating properly (myometrium and endometrium). Owing to the increase in the prevalence of gynecological diseases over the past several years, the market for gynecology medications has grown significantly. Global female population lifestyle changes have gradually increased their need for high-end medical care requirements. Owing to the increase in the prevalence of gynecological diseases over the past several years, the market for gynecology medications has grown significantly. Also, changing lifestyle of women and the growing working population of women demands high-end medical care requirements. Owing to such a growing need for gynecology medicines drives the growth of prescription hormonal drugs in the gynecology industry. For instance, in December 2019, Drug firm Mankind Pharma launched its generic ‘Dydrogesterone’ tablets for the treatment of infertility and pregnancy-related complications in the Indian market. Such growing innovations and drugs launched for gynecology treatment and growing demand for hormonal drugs fuel the growth of Prescription Hormonal Drugs in Gynecology Industry over the forecast period 2022-2027.
Prescription Hormonal Drugs In Gynecology Market Report Coverage
The report: “Prescription Hormonal Drugs In Gynecology Market Forecast
(2022-2027)" by Industry ARC, covers an in-depth analysis of the following
segments in the Prescription Hormonal Drugs In Gynecology Market.
by Indication: Cervical
Dysplasia, Menstrual Disorders, Pelvic Floor Prolapse, Pelvic Pain, Polycystic
Ovarian Syndrome, Uterine Fibroids, Urinary Incontinence and Others.
by Drugs: Hydroxy Progesterone, Estradiol,
Levonorgestrel, Norethindrone, Follicle Stimulating Hormone, Leuprolide and
Others.
by Mode of Administration: Oral, Injectable, Vaginal, Sublingual, Buccal, Rectal and Others.
by Distribution Channels: Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.
by Geography:
North America (the U.S., Canada and Mexico), Europe (Germany, United Kingdom (UK),
France, Italy, Spain, Russia and the Rest of Europe), Asia Pacific (China,
Japan India, South Korea, Australia and New Zealand and Rest of Asia Pacific),
South America (Brazil, Argentina, Chile, Colombia and Rest of South America)
and Rest of the World (the Middle East and Africa).
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021, owing to the noticeable gynecological disease in this region fueling the growth of the Prescription Hormonal Drugs In Gynecology Market Size in this region.
- The Prescription Hormonal Drugs In Gynecology Market is predicted to increase owing to the growing incidence of pre and post-menstrual problems and other gynecological diseases in women.
- However, the low awareness about menstrual health in underdeveloped countries may limit market growth over the forecast period 2022-2027.
- A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Prescription Hormonal Drugs In Gynecology Market Report.
Prescription Hormonal Drugs In Gynecology Market Segment Analysis -
by Indication
Prescription Hormonal Drugs In Gynecology Market based on Indication
can be further segmented into Cervical Dysplasia, Menstrual Disorders, Pelvic
Floor Prolapse, Pelvic Pain, Polycystic Ovarian Syndrome, Uterine Fibroids, Urinary
Incontinence and Others. Pelvic Pain held a dominant share in the year
2021. This is owing to the high experience of pelvic pain by most women
during menstruation. Also, pelvic pain is a possible symptom of urinary tract
infections or gastrointestinal issues, it also indicates a problem with organs
in the pelvic area. It also relates to chronic pelvic inflammatory disease, ovarian
remnant, fibroids, pelvic congestion syndrome and other diseases. Such high
relation of pelvic pain with the number of diseases drives the growth of Prescription
Hormonal Drugs in the Gynecology Market Share.
However, the Uterine
Fibroids segment is estimated to grow with the
fastest CAGR of 6.1% over the forecast period 2022-2027. This is owing
to growing cases of uterine fibroids in women. According to a research paper
published in the Journal of Women Health in August 2021, Approximately, 30%–35%
of women will be diagnosed with fibroids using ultrasound detection and over
70% of women are estimated to develop fibroids by age 50. Such growing
prevalence of uterine fibroids in women and the need for medication fuel
the growth of the Prescription Hormonal Drugs In Gynecology Market Share over the forecast period 2022-2027.
Prescription Hormonal Drugs In Gynecology Market Segment Analysis - by Distribution Channels
Prescription Hormonal Drugs In Gynecology Market based on the distribution
channels can be further segmented into Hospital Pharmacies, Retail Pharmacies
and Online Pharmacies. The Hospital Pharmacies segment held a dominant market
share in the year 2021. This is attributed to the increased visit of women to
hospitals for various gynecological treatments. According to the Cleveland
Clinic, approximately 40% to 80% of women experience fibroids. Also, about
250,000 to 1 million cisgender women in the U.S. get diagnosed with cervical
dysplasia each year. Such growing cases of menstrual disorders in women
resulted in frequent visits to hospitals for prescription medicines such as medroxyprogesterone,
leuprorelin, thyrotropic, lactogenic, adrenotropic and others. Such high cases
of gynecological disorders and increased visits to hospitals surge demand for
hospital pharmacies for prescription medicines and drive the growth of the Prescription Hormonal Drugs In Gynecology Market Share over the forecast period 2022-2027.
However, Online Pharmacies are estimated
to grow with the fastest CAGR of 7.5% over the forecast period 2022-2027.
This is the result of the easy availability of prescription medicines with
consultancy on the online platform. With the development of e-commerce platforms,
most of the key market players build their own websites and applications to
directly contact consumers shed the middle distribution chain of wholesalers
and retailers and make able to give huge discounts to consumers on prescription
hormonal drugs such as medroxyprogesterone, leuprorelin, thyrotropic,
lactogenic, adrenotropic and others. As the online system give benefit to the
company and consumer the growth of online pharmacies is anticipated to hike in the
forecast period, which fuels the growth of the Prescription Hormonal Drugs In Gynecology Market Share over the forecast period 2022-2027.
Prescription Hormonal Drugs In Gynecology Market Segment Analysis - by Geography
The Prescription Hormonal Drugs In Gynecology Market based on
Geography can be further segmented into North America, Europe, Asia-Pacific,
South America and the Rest of the World. North America held a dominant market
share of 31% in the year 2021. This is owing to high awareness of women’s
health and also the high spending capacity of women. About 85% of consumer
spending is controlled or influenced by women, who make up more than half of
the population in the United States as per Forbes 2019. According to the U.S.,
Department of Health & Human Services, heavy periods affect one in five
American women each year. And women with myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS) have a higher risk for heavy bleeding. Also, approximately
25% of U.S., women with uterine fibroids will experience symptoms severe enough
to require treatment. Such growing requirement for treatment, awareness about women’s
health and high spending capacity of women in this region surge demand for
prescription hormonal drugs like medroxyprogesterone, leuprorelin, thyrotropic,
lactogenic, adrenotropic and others. Such growing demand for prescription
hormonal drugs drives the growth of the Prescription Hormonal Drugs In Gynecology Market Size.
Furthermore, Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. This is the result of the percentage of women population in this region. According to WorldBank in 2021, the percentage of women population in East Asia and the Pacific is 49.3%. According to the World Health Organization (WHO), 1.2 billion women will be over the age of 50 in 2030, making it very difficult to stop menopause from taking off in the coming years. In Asia, 373 million women will be in menopause by 2025. Hormonal drugs such as medroxyprogesterone, leuprorelin, thyrotropic, lactogenic and adrenotropic, play an important role at the time of menopause by controlling the hormonal balance of the body and reducing common menopausal symptoms. Such use of prescription hormonal drugs in menopause and their growing demand fuel the growth of the Prescription Hormonal Drugs In Gynecology Market Size over the forecast period 2022-2027.
Prescription Hormonal Drugs In Gynecology Market Drivers
Various Initiatives by Governmental Organisations for Awareness Regarding Gynecological Issues to Fuel Market Growth.
According to World Health Organisation (WHO), about 500 million women and girls struggle to access menstrual products or safe, private, hygienic spaces in which to use them. To spread awareness about menstrual hygiene and to minimize related diseases and weaknesses in women various governments and organizations drive a number of programs for women’s health. The Indian government launched Menstrual Hygiene Scheme (MHS), in 107 selected districts in 17 States wherein a pack of six sanitary napkins called “Freedays” was provided to rural adolescent girls for INR 6. In May 2021, the Rajasthan government allocated Rs 200 crore to the Free Medicine Scheme, which was also spent on menstrual hygiene products. Such governments and organizations working for awareness of menstrual health create demand for hormonal drugs and drive the growth of the Prescription Hormonal Drugs in Gynecology Industry over the forecast period 2022-2027.
Growing Number of Employed Women Leading to Hectic Lifestyle is Driving the Market Growth.
With growing urbanization and change in lifestyle, the involvement
of women in various industries is increasing. According to the Bureau of Labour
Statistics percentage of women in the workforce is 58% in February 2022. Also,
according to the current population survey, the average annual earning of women
in 2020, is $53,731. Owing to growing employment among women and their
purchasing power, they are able to invest in their wellness. More than half
(57%) of women report taking at least one prescription medicine on a regular
basis, including oral contraceptives as employment KFF Women's Health Survey
2020. Such an increase in the rate of employment for women and the ability to
spend on wellness drive the growth of the Prescription Hormonal Drugs in
Gynecology Industry over the forecast period 2022-2027.
Prescription Hormonal Drugs In Gynecology Market Challenge
High Cost of Hormonal Therapy is Hampering Market Growth
The cost of hormonal therapy is very high in middle- and
low-income countries. According to a research article published in the National
Center of Biotechnology Information in November 2021, the lifetime cost of
hormone therapy with tamoxifen and switch therapy was to be 1,472,037 and 1,281,811.
Such a high cost of treatment is out of pocket for people with low and middle
income and increases their healthcare burden. Such a high cost of treatment for
people with low and middle-income levels may hamper the growth of Prescription
Hormonal Drugs in Gynecology Industry.
Prescription Hormonal Drugs in Gynecology Industry Outlook
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Prescription Hormonal Drugs In Gynecology Market. The top 10 companies in the Prescription Hormonal Drugs In Gynecology Market are:
- Eli Lilly and Company
- Pfizer, Inc.,
- Merck & Co.
- Amgen Inc.
- AstraZeneca
- F. Hoffmann-La Roche Ltd.
- Allergan Plc
- Bayer AG.
- Duramed
Pharmaceuticals
- Berlex
Laboratories
Recent Developments
- In January 2022, a new research, development and commercialization partnership between Pfizer Inc. and BioNTech SE has been announced in an effort to create the first possible mRNA-based vaccine for the treatment of shingles (herpes zoster virus or HZV). The parties to the agreement will use BioNTech's unique mRNA platform technology and a proprietary antigen technology discovered by Pfizer scientists for the COVID-19 vaccine. The partners will split the costs of development.
- In July 2021, Eli Lilly and Company announced that it has acquired private biotech firm Protomer Technologies. To find and create molecules that can detect glucose or other endogenous modulators of protein activity, Protomer uses its patented peptide and protein engineering platform. The company can create therapeutic proteins and peptides with tunable activity that can be regulated by tiny molecules owing to its patented chemical biology-based platform.
- In February 2021, Merck and Pandion Therapies, Inc. declared that they had signed a legally binding agreement under which Merck would pay $1.85 billion to buy Pandion, a biotechnology business in the clinical stages of developing innovative therapeutics to meet the unmet needs of patients with autoimmune illnesses. In order to selectively activate and expand regulatory T cells (Tregs) for the possible therapy of ulcerative colitis and other autoimmune diseases, the company's flagship candidate, PT101, is an engineered IL-2 mutein linked to a protein backbone.
Relevant Titles
Report Code: HCR 0266
Report Code: HCR 0267
Report Code: HCR 92870